Previous 10 | Next 10 |
Thinly traded micro cap Kezar Life Sciences (NASDAQ: KZR ) is up 2% after hours on the heels of positive data from the Phase 1b open-label dose-escalation portion of its Phase 1/2 study of KZR-616 in patients with systemic lupus erythematosus (SLE). The results were presented...
Repeat dosing of KZR-616 demonstrates tolerability and broad and consistent evidence of efficacy across multiple measures of disease activity Patients receiving KZR-616 have not experienced the hematologic and constitutional toxicities seen with approved nonselective proteasome inhibit...
SOUTH SAN FRANCISCO, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that Company mana...
Gainers: Soliton (NASDAQ: SOLY ) +124% . Exela Technologies (NASDAQ: XELA ) +33% . Flexible Solutions International (NYSEMKT: FSI ) +24% . IMAC Holdings (NASDAQ: IMAC ) +20% . Biocept (NASDAQ: BIOC ) +21% . Anaplan (NYSE: PLAN ) +18% . MYnd Analytics (NASDAQ: MYND ) +18% . Sea...
Thinly traded micro cap Kezar Life Sciences (NASDAQ: KZR ) slumps 29% premarket average volume in reaction to preliminary data from the first two cohorts in an open-label dose-escalation study of lead drug KZR-616 in patients with systemic lupus erythematosus (SLE). The results...
Abstract highlights preliminary results from the first two cohorts of the Phase 1b portion of the MISSION Trial in patients with systemic lupus erythematosus (SLE) Detailed poster with additional results will be presented during EULAR 2019 in Madrid SOUTH SAN FRANCISCO, Calif., May 2...
SOUTH SAN FRANCISCO, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that members of th...
Kezar Life Sciences (NASDAQ: KZR ): Q1 GAAP EPS of -$0.40 beats by $0.03 . More news on: Kezar Life Sciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Phase 1b systemic lupus erythematosus (SLE) top-line data release and Phase 2 lupus nephritis (LN) initiation on track in Q2 2019 Site selection underway for Phase 2 trial of KZR-616 for the treatment of dermatomyositis (DM) and polymyositis (PM)—trial on track to begin in 2H 20...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...